-+ 0.00%
-+ 0.00%
-+ 0.00%

Artiva Biotherapeutics to present updated AB-101 AlloNK plus rituximab Sjögren disease data at ISSjD 2026

PUBT·09/23/2026 11:30:25
Listen to the news
Artiva Biotherapeutics to present updated AB-101 AlloNK plus rituximab Sjögren disease data at ISSjD 2026
  • Artiva Biotherapeutics flagged updated clinical data for AB-101 with rituximab in Sjögren disease for future oral presentation on Oct. 1, 2026.
  • Early results in 11 patients showed strong efficacy signals, supporting the company’s strategy to pair its NK-cell therapy with anti-CD20 antibodies.
  • The program is positioned for outpatient use, a potential differentiator for adoption and commercial rollout in community rheumatology settings.
  • Artiva also plans to start a Phase 3 registrational trial of AB-101 in refractory rheumatoid arthritis in the second half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230730PRIMZONEFULLFEED9832157) on September 23, 2026, and is solely responsible for the information contained therein.